Powder -20℃ 3 years; 4℃ 2 years In solvent -80℃ 6 months;-20℃ 1 month
研究领域：
Cancer
Target：
IC50: 2.7 nM (Akt1), 14 nM (Akt2), 8.1 nM (Akt3)
描述：
Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively.
m.cnreagent.com
